



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-019-A)

In the Application of: )  
 )  
Guiping Li, et al. )  
 )  
Serial No. 10/038,069 ) Examiner: Habte, Kahsay  
 )  
Filed: December 21, 2001 ) Art Unit: 1624  
 )  
For: Benzimidazole and Pyridylmidazole )  
Derivatives As Ligands for GABA<sub>A</sub> Receptors )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

**Foreign Documents**

1. WO 02/092575 A1 published 21 November 2002.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Pursuant to MPEP Section 609 and 37 C.F.R. Section 1.97 (e) (2), the undersigned certifies that no item of information referenced herein was cited in a communication from a foreign patent office in a counterpart foreign application. The undersigned further certifies that, to his knowledge, no information referenced herein was known to any individual designated in 37 C.F.R. Section 1.56 more than three months prior to the filing of this statement.

Respectfully submitted,

McDONNELL BOEHNEN  
HULBERT & BERGHOFF  
300 South Wacker Drive  
Chicago, Illinois 60606  
(312) 913-0001

Dated: June 7, 2004

By: 

Steven J. Sarussi  
Reg. No. 32,784

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

01-019-A

Serial No.

10/038,069

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Guiying Li, et al.

**Filing Date:**

December 21, 2001

**Group:**

# 1624

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	WO 02/092575 A1	11/21/2002	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.